Fewer than 10% of individuals who could benefit from GLP-1 drugs including Wegovy can access them, warns the global health agency as it issues its inaugural recommendations on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is urging increased and just access to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our new guidelines affirms that excess weight is a long-term condition that can be addressed with thorough and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are key barriers to universal access to the treatments that can assist patients in reducing substantial body mass, explains the body.
Skinny Jab Shortage
Even under the present most favorable scenario, the manufacturing of such drugs could only cover around 100 million people – fewer than 10% of those who need them, per the WHO.
The recommendation urges governments and firms to widen access, through measures such as licensing agreements.
The intellectual property rights on the active ingredient – the main component of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
The Way Obesity Jabs Operate
The injections mimick a natural hormone to slow digestion, suppress the appetite and boost feelings of fullness so users reduce food intake.
Patients commonly start to lose weight after several weeks of starting on the weekly injections.
Evidence points to patients may regain a significant portion within a year of discontinuing the medication, as their normal hunger come back.
To be above a healthy weight elevates your likelihood for experiencing health problems, such as diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight impacts individuals in countries worldwide and was responsible for millions of fatalities worldwide in 2024, according to the health agency.
